ENDO INTERNATIONAL PLC (NASDAQ:ENDP) Files An 8-K Other EventsItem 8.01.Other Events.
On January 11, 2018, Endo International plc (“Endo”) issued a press release announcing that its subsidiary, Endo Pharmaceuticals Inc. (“EPI”), has received a grand jury subpoena from the United States Attorney’s Office for the Southern District of Florida seeking documents and information relating to products containing oxymorphone. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
To Endo’s knowledge, no proceedings have currently been initiated against EPI as a result of the subpoena, although Endo cannot predict whether or when proceedings might be initiated. Endo and EPI intend to be responsive to the subpoena and cooperate with any related government investigation. Neither Endo nor EPI can make assurances as to the time or resources that will need to be devoted to this inquiry or its final outcome, or the impact of this inquiry or any proceedings on Endo’s consolidated financial condition, results of operations and cash flows.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits.
Endo International plc ExhibitEX-99.1 2 exhibit991opanapressreleas.htm EXHIBIT 99.1 OPANA PR 2018 Exhibit 99.1 Opana Press Release 2018 EXHIBIT 99.1Endo Comments on United States Attorney’s Office Grand Jury Subpoena Relating to Products Containing OxymorphoneDUBLIN,…To view the full exhibit click here
